Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Raphael

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Harefuah|February 23, 2022
[GENOMIC PROFILING IN LUMINAL BREAST CANCER]Ari Raphael, Amir Sonnenblick
NPJ Systems Biology and Applications|August 8, 2025
Breast cancer is detectable from peripheral blood using machine learning over T cell receptor repertoiresMiriam Zuckerbrot-Schuldenfrei, Ari Raphael, Alona Zilberberg, et al.
BMC Medical Research Methodology|January 8, 2022
Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional studyNethanel Asher, Ari Raphael, Ido Wolf, et al.
Breast Cancer Research and Treatment|April 7, 2024
Body composition measures as a determinant of Alpelisib related toxicityEliya Shachar, Ari Raphael, Uriel Katz, et al.
Genes|October 27, 2022
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus TreatmentAri Raphael, Mali Salmon-Divon, Jessica Epstein, et al.
JCO Oncology Practice|March 25, 2026
Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World CohortEliya Shachar, Uriel Katz, Shir Barilier, et al.
Journal of Clinical Medicine|March 17, 2025
Real-World Data on Osimertinib-Associated Cardiac ToxicityAbed Agbarya, Ari Raphael, Hadas Gantz Sorotsky, et al.
Life (Basel, Switzerland)|August 26, 2022
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?David Zahler, Joshua H Arnold, Tali Bar-On, et al.
Clinical Cardiology|January 20, 2023
High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracyclineRanny Baruch, David Zahler, Lior Zornitzki, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter StudyItamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Harefuah|February 23, 2022
[GENOMIC PROFILING IN LUMINAL BREAST CANCER]Ari Raphael, Amir Sonnenblick
NPJ Systems Biology and Applications|August 8, 2025
Breast cancer is detectable from peripheral blood using machine learning over T cell receptor repertoiresMiriam Zuckerbrot-Schuldenfrei, Ari Raphael, Alona Zilberberg, et al.
BMC Medical Research Methodology|January 8, 2022
Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional studyNethanel Asher, Ari Raphael, Ido Wolf, et al.
Breast Cancer Research and Treatment|April 7, 2024
Body composition measures as a determinant of Alpelisib related toxicityEliya Shachar, Ari Raphael, Uriel Katz, et al.
Genes|October 27, 2022
Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus TreatmentAri Raphael, Mali Salmon-Divon, Jessica Epstein, et al.
JCO Oncology Practice|March 25, 2026
Comparable Effectiveness of Weight-Based and Fixed-Dose Pembrolizumab in Non-Small Cell Lung Cancer: Insights From a National Real-World CohortEliya Shachar, Uriel Katz, Shir Barilier, et al.
Journal of Clinical Medicine|March 17, 2025
Real-World Data on Osimertinib-Associated Cardiac ToxicityAbed Agbarya, Ari Raphael, Hadas Gantz Sorotsky, et al.
Life (Basel, Switzerland)|August 26, 2022
Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction?David Zahler, Joshua H Arnold, Tali Bar-On, et al.
Clinical Cardiology|January 20, 2023
High neutrophil-to-lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracyclineRanny Baruch, David Zahler, Lior Zornitzki, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter StudyItamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Pageof 2